Analysts Offer Insights on Healthcare Companies: Agilent (A), Natera (NTRA) and Nektar Therapeutics (NKTR)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agilent (A – Research Report), Natera (NTRA – Research Report) and Nektar Therapeutics (NKTR – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Agilent (A)
Morgan Stanley analyst Kallum Titchmarsh reiterated a Buy rating on Agilent on March 11 and set a price target of $160.00. The company’s shares closed last Thursday at $111.63.
According to TipRanks.com, Titchmarsh is a 2-star analyst with an average return of
Currently, the analyst consensus on Agilent is a Strong Buy with an average price target of $163.62, which is a 44.1% upside from current levels. In a report issued on February 26, TipRanks – PerPlexity also upgraded the stock to Buy with a $138.00 price target.
See today’s best-performing stocks on TipRanks >>
Natera (NTRA)
In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Natera, with a price target of $285.00. The company’s shares closed last Thursday at $190.31.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Natera has an analyst consensus of Strong Buy, with a price target consensus of $262.40, representing a 35.4% upside. In a report issued on February 27, TD Cowen also maintained a Buy rating on the stock with a $280.00 price target.
Nektar Therapeutics (NKTR)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics, with a price target of $105.00. The company’s shares closed last Thursday at $70.36.
According to TipRanks.com, Rahimi is a 5-star analyst with an average return of
Nektar Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $122.42, a 68.9% upside from current levels. In a report issued on March 2, BTIG also maintained a Buy rating on the stock with a $151.00 price target.
